-- Abbott Laboratories (ABT) said Tuesday that it received US Food and Drug Administration clearance and the European Union's CE Mark for its Ultreon 3.0 artificial intelligence-powered coronary imaging software.
The software uses optical coherence tomography to support doctors performing minimally invasive procedures to open blocked heart arteries, known as percutaneous coronary intervention, the company said.
Abbott said the software helps doctors choose the best stent location and size to improve blood flow, thereby enabling faster, more precise procedures.
Shares of the company were up 1.1% in Tuesday's trading.
Price: $93.58, Change: $+0.78, Percent Change: +0.84%